Actively Recruiting

Early Phase 1
Age: 18Years +
All Genders
NCT05851378

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Led by Robert Bok, MD, PhD · Updated on 2026-01-12

40

Participants Needed

1

Research Sites

211 weeks

Total Duration

On this page

Sponsors

R

Robert Bok, MD, PhD

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.

CONDITIONS

Official Title

Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must be older than 18 years with evidence of evaluable disease (contrast enhancing lesion or non-enhancing lesion larger than 1 cubic centimetre)
  • Cohort 1: Participants with IDH mutant glioma who may or may not have received prior treatment
  • Cohort 2: Participants with recurrent IDH mutant glioma before surgical resection
  • Participants must have prior MR scans available to assess tumor location and size
  • Participants must have no contraindications for magnetic resonance examinations
  • Participants must have a life expectancy greater than 8 weeks
  • Participants must have a Karnofsky performance status above 70
  • Participants must have adequate kidney function (creatinine less than 1.5 mg/dL), tested within 60 days prior to imaging
  • Participants must not have significant medical illnesses that cannot be controlled or would interfere with study participation
  • Participants must not have New York Heart Association Grade II or higher congestive heart failure
  • Participants must not have had a myocardial infarction or unstable angina within 12 months before enrollment
  • Both males and females of all races can participate
  • Participants must sign informed consent and authorization for release of health information
  • Participants may not be known to be HIV-positive (HIV testing not required)
  • Participants must not have history of other cancers except non-melanoma skin cancer or carcinoma in-situ of the cervix, unless in complete remission and off therapy for at least 3 years
  • Participants must not be pregnant or breastfeeding; women of childbearing potential must have a negative pregnancy test within 14 days before imaging and use effective contraception
Not Eligible

You will not qualify if you...

  • Participants unable to comply with study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

Loading map...

Research Team

W

Wendy Ma

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here